Study of the activity of PD-1 inhibitors in metastatic uveal melanoma
The aim of the research is to study the activity of PD-1 inhibitors in patients with metastatic uveal melanoma and treated by Nivolumab and Pembrolizumab. These molecules have already received the authorities approvals. The data collected will be crucial for the understanding of the mechanism of PD-1 inhibitors and also for the futures studies.
Study Type
OBSERVATIONAL
Enrollment
100
Rodrigues
Paris, Île-de-France Region, France
Response rate Data collection of the efficacity of PD-1 inhibitors
Description of Response rate
Time frame: December 2019
Progression Free Survival Data collection of the efficacity of PD-1 inhibitors
Description of PFS (Progression Free Survival)
Time frame: December 2019
Global Survival Data collection of the efficacity of PD-1 inhibitors
Description of Global Survival
Time frame: December 2019
Stability Data collection of the efficacity of PD-1 inhibitors
Description of Stability at 6 months
Time frame: December 2019
Objective response Data collection of the efficacity of PD-1 inhibitors
Description of Objective response
Time frame: December 2019
Exploration of PD-1 inhibitors biomarkers
The study of PD-1 inhibitors biomarkers could be useful to identify a group of patients whose the molecules are most activated and then for futures studies.
Time frame: December 2019
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.